Saturday, October 18, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Nasdaq

Viracta Therapeutics Ceases Operations Following Nasdaq Delisting

Dieter Jaworski by Dieter Jaworski
September 2, 2025
in Nasdaq, Pharma & Biotech, Turnaround
0
Viracta Therapeutics Stock
0
SHARES
159
VIEWS
Share on FacebookShare on Twitter

Viracta Therapeutics has officially terminated all business activities, marking a complete wind-down of the company. The firm’s website now confirms the full cessation of operations, concluding what was once a promising venture in the precision oncology sector.

Financial Collapse Triggers Immediate Liquidation

The company’s board of directors enacted an immediate liquidation plan on February 5, 2025, resulting in the termination of all employees. This decisive action came directly on the heels of the company’s delisting from the Nasdaq exchange, which occurred just one day prior. The delisting was triggered after Viracta’s stock price fell below the mandatory minimum $1 listing requirement.

In conjunction with the liquidation, the entire executive leadership team resigned. The board appointed Craig Jalbert from the accounting firm Verdolino & Lowey to serve as the sole officer responsible for managing the wind-down process. His appointment is set for a three-year term with an annual salary of $50,000. The company’s dire financial state, characterized by a current ratio of 0.76 and short-term liabilities that significantly exceeded its available cash, left no viable alternative to liquidation.

Clinical Progress Undone by Financial Shortfall

This operational collapse stands in stark contrast to the encouraging clinical data Viracta had reported mere months earlier. In August 2024, the company announced positive Phase 2 results for Nana-val, its combination therapy targeting EBV-positive lymphomas. The data demonstrated substantial anti-tumor activity and a favorable tolerability profile for the treatment.

Should investors sell immediately? Or is it worth buying Viracta Therapeutics?

Despite this clinical promise, the company was simultaneously fighting for its survival. A series of drastic cost-cutting measures failed to secure its future:
* The lymphoma clinical trial was halted in January 2025
* The entire EBV-positive lymphoma program was terminated in December 2024
* The workforce was reduced through two separate rounds of layoffs (42% and 23%) within a few months

Ultimately, a critical lack of funding prevented Viracta from capitalizing on its clinical successes and advancing its programs.

Shareholders Face a Total Loss

For the company’s investors, the liquidation signifies a complete financial loss. Viracta’s shares were last quoted at a mere $0.0080, rendering them virtually worthless. The wind-down process will prioritize satisfying creditor claims, with no expectation of any recovery for equity holders.

While the formal search for “strategic alternatives” for the company’s development programs may technically continue, the outcome for shareholders remains unchanged: a total loss of investment. Viracta Therapeutics has ceased to exist.

Ad

Viracta Therapeutics Stock: Buy or Sell?! New Viracta Therapeutics Analysis from October 17 delivers the answer:

The latest Viracta Therapeutics figures speak for themselves: Urgent action needed for Viracta Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 17.

Viracta Therapeutics: Buy or sell? Read more here...

Tags: Viracta Therapeutics
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Intel Stock
Earnings

Intel’s High-Stakes Transformation: Workforce Cuts and Price Hikes Signal Critical Juncture

October 17, 2025
United Parcel Service Stock
Analysis

UPS Shares Face Mounting Pressure as Cost-Cutting Intensifies

October 16, 2025
Meta Stock
AI & Quantum Computing

Meta Accelerates AI Strategy with Major Infrastructure Push

October 16, 2025
Next Post
SPDR® S&P Bank ETF Stock

Banking Sector Rally Gains Momentum on Shifting Interest Rate Outlook

Oracle Stock

Oracle Shares Face Critical Test Ahead of Earnings Release

Nio Stock

Nio's Resurgence: Can the Chinese EV Maker Sustain Its Momentum?

Recommended

Uranium Energy Stock

Uranium Energy Shares Reach Unprecedented Highs Amid Sector Optimism

1 month ago
10X Genomics Stock

10X Genomics Stock: A Study in Market Contradictions

1 month ago
Johnson & Johnson Stock

Johnson & Johnson Commits $2 Billion to Bolster US Manufacturing Base

2 months ago
Biotechnology Stock Market Today (1)

Nektar Therapeutics Secures 30 Million Financing Agreement with TCGX

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Nike NIO Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Autoliv’s Q3 2025 Results: A Critical Test for Investors

Itron’s Strategic Expansion: AI Acquisition and EV Initiatives Fuel Market Optimism

Coca-Cola Shares Defy Strong Earnings with Unexpected Decline

UPS Shares Face Mounting Pressure as Cost-Cutting Intensifies

Intel’s AI Ambitions Face Market Skepticism Despite Recent Stock Rally

Applovin Shares Surge on Wave of Analyst Optimism

Trending

Intel Stock
Earnings

Intel’s High-Stakes Transformation: Workforce Cuts and Price Hikes Signal Critical Juncture

by Dieter Jaworski
October 17, 2025
0

The semiconductor industry is experiencing unprecedented growth, fueled by massive global investments in artificial intelligence capabilities. At...

LeonardoADR Stock

LeonardoADR Shares Gain Momentum Ahead of Earnings Report

October 17, 2025
Extreme Networks Stock

Enterprise Networking Specialist Gains AI-Driven Market Leadership

October 17, 2025
Autoliv Stock

Autoliv’s Q3 2025 Results: A Critical Test for Investors

October 17, 2025
Itron Stock

Itron’s Strategic Expansion: AI Acquisition and EV Initiatives Fuel Market Optimism

October 17, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Intel’s High-Stakes Transformation: Workforce Cuts and Price Hikes Signal Critical Juncture
  • LeonardoADR Shares Gain Momentum Ahead of Earnings Report
  • Enterprise Networking Specialist Gains AI-Driven Market Leadership

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com